Q-omics provides the consensus-scored LINC00115 profile across patient tissues and cancer cell-line models. LINC00115 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00115 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LINC00115 RNA expression shows 17,218 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where LINC00115 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00115 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00115 survival associations across molecular data types. LINC00115 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00115 RNA expression–survival associations across cancer types. High LINC00115 expression shows unfavorable associations in KIRC, ACC, COAD, KIRP and SARC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00115 RNA expression.
This table summarizes LINC00115 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00115. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00115 shows higher tumor expression in HNSC, BLCA, COAD, STAD, LUAD and LIHC. The HNSC box plot shows higher LINC00115 RNA expression in tumor versus normal tissue (log2 FC = +0.538, t-test p < 0.001).
This table shows molecular features associated with LINC00115 in patient tissues and cancer cell lines. In patient samples, LINC00115 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC00115 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in NCI60_ALL.
